Revenue Breakdown
Composition ()
No data
Revenue Streams
Canopy Growth Corp (CGC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Canadian adult-use cannabis, accounting for 35.9% of total sales, equivalent to CAD 23.94M. Other significant revenue streams include Canadian medical cannabis and Storz and Bickel. Understanding this composition is critical for investors evaluating how CGC navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Canopy Growth Corp maintains a gross margin of 28.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -16.99%, while the net margin is -84.02%. These profitability ratios, combined with a Return on Equity (ROE) of -48.50%, provide a clear picture of how effectively CGC converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CGC competes directly with industry leaders such as CVGW and MGPI. With a market capitalization of $432.41M, it holds a significant position in the sector. When comparing efficiency, CGC's gross margin of 28.80% stands against CVGW's 9.34% and MGPI's 34.89%. Such benchmarking helps identify whether Canopy Growth Corp is trading at a premium or discount relative to its financial performance.
